Bonner said anyone exhibiting symptoms of the disease should make an appointment with Student Health and Wellness for ...

Meningococcal vaccines protect against bacterial infections caused by Neisseria meningitidis. These bacteria are capable of causing meningococcal meningitis, a condition that causes inflammation of ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

The vaccine is an injectable suspension for intramuscular use that combines components of GlaxoSmithKline's 2 well-established meningococcal vaccines, Bexsero and Menveo. HealthDay News — The U.S.

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

GSK’s MenABCWY vaccine is an injectable suspension intended for intramuscular use. It comes with a vial of lyophilised MenACWY powder, mixed with a prefilled syringe of MenB liq ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).